Increasing trend of antimicrobial resistance in Shigella associated with MSM transmission in Barcelona, 2020-21: outbreak of XRD Shigella sonnei and dissemination of ESBL-producing Shigella flexneri.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
03 04 2023
03 04 2023
Historique:
received:
06
09
2022
accepted:
23
01
2023
medline:
4
4
2023
pubmed:
11
2
2023
entrez:
10
2
2023
Statut:
ppublish
Résumé
Several countries have recently reported the detection of ESBL-producing Shigella sonnei associated with transmission among MSM. In a previous study by our group, 2.8% of Shigella spp. obtained from MSM in Barcelona between 2015 and 2019 were ESBL producers. To describe and characterize the emerging ESBL-producing Shigella spp. associated with sexual transmission among MSM detected from 2020 to 2021 in Barcelona, elucidating their connectivity with contemporaneous ESBL-producing Shigella spp. from other countries. From 2020 to 2021, we identified that among MSM, 68% of S. sonnei were XDR harbouring blaCTX-M-27 and 14% of Shigella flexneri were MDR harbouring blaCTX-M-27. WGS analysis showed that the ESBL-producing S. sonnei were part of a monophyletic cluster, which included isolates responsible for the prolonged outbreak occurring in the UK. Our data also reveal the first emergence and clonal dissemination of ESBL-producing and fluoroquinolone-resistant S. flexneri 2a among MSM. We report an increasing trend of antimicrobial resistance in Shigella spp. among MSM in Barcelona since 2021, mainly as a consequence of the dissemination of XDR ESBL-producing S. sonnei, previously reported in the UK. These results highlight the importance of international collaborative surveillance of MDR/XDR S. sonnei and S. flexneri for rapid identification of their emergence and the prevention of the transmission of these pathogens.
Sections du résumé
BACKGROUND
Several countries have recently reported the detection of ESBL-producing Shigella sonnei associated with transmission among MSM. In a previous study by our group, 2.8% of Shigella spp. obtained from MSM in Barcelona between 2015 and 2019 were ESBL producers.
OBJECTIVES
To describe and characterize the emerging ESBL-producing Shigella spp. associated with sexual transmission among MSM detected from 2020 to 2021 in Barcelona, elucidating their connectivity with contemporaneous ESBL-producing Shigella spp. from other countries.
RESULTS
From 2020 to 2021, we identified that among MSM, 68% of S. sonnei were XDR harbouring blaCTX-M-27 and 14% of Shigella flexneri were MDR harbouring blaCTX-M-27. WGS analysis showed that the ESBL-producing S. sonnei were part of a monophyletic cluster, which included isolates responsible for the prolonged outbreak occurring in the UK. Our data also reveal the first emergence and clonal dissemination of ESBL-producing and fluoroquinolone-resistant S. flexneri 2a among MSM.
CONCLUSIONS
We report an increasing trend of antimicrobial resistance in Shigella spp. among MSM in Barcelona since 2021, mainly as a consequence of the dissemination of XDR ESBL-producing S. sonnei, previously reported in the UK. These results highlight the importance of international collaborative surveillance of MDR/XDR S. sonnei and S. flexneri for rapid identification of their emergence and the prevention of the transmission of these pathogens.
Identifiants
pubmed: 36760088
pii: 7033728
doi: 10.1093/jac/dkad031
pmc: PMC10068420
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
975-982Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Lancet Infect Dis. 2022 Oct;22(10):1503-1510
pubmed: 35809593
J Glob Antimicrob Resist. 2020 Jun;21:417-419
pubmed: 31866575
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Clin Infect Dis. 2019 Oct 15;69(9):1535-1544
pubmed: 30615105
Antimicrob Agents Chemother. 2020 Nov 17;64(12):
pubmed: 33020158
HIV Med. 2015 Mar;16(3):168-75
pubmed: 25656740
J Antimicrob Chemother. 2021 Dec 24;77(1):89-97
pubmed: 34673959
Int J Antimicrob Agents. 2021 Sep;58(3):106378
pubmed: 34157402
Nat Commun. 2021 May 11;12(1):2684
pubmed: 33976138
Emerg Microbes Infect. 2022 Dec;11(1):498-506
pubmed: 35045788
Clin Infect Dis. 2017 Nov 29;65(12):e45-e80
pubmed: 29053792
Emerg Microbes Infect. 2022 Dec;11(1):172-181
pubmed: 34842496
Paediatr Int Child Health. 2018 Nov;38(sup1):S50-S65
pubmed: 29790845
Emerg Infect Dis. 2016 Nov;22(11):1948-1952
pubmed: 27767929
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32718957
Microbiol Spectr. 2022 Jun 29;10(3):e0233721
pubmed: 35647695
Nat Commun. 2018 Apr 13;9(1):1462
pubmed: 29654279
Microb Genom. 2021 Aug;7(8):
pubmed: 34427554
Sci Rep. 2018 May 9;8(1):7389
pubmed: 29743642
J Med Microbiol. 2021 Oct;70(10):
pubmed: 34665107